Please assess the completion status of the following clinical trial:

Trial Title: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of HF ≥ 3 months, with either preserved or reduced LVEF~2. Diagnosis of NYHA Class III HF (historical assessment documented at screening visit)~3. Subjects with reduced LVEF must be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be stable for one month prior to study entry.~4. At least 1 HF hospitalization within 12 months of Screening Visit~5. Subjects with pulmonary artery branch diameter sized between 7mm and 15mm (implanted vessel)~Exclusion Criteria:~1. Subjects with history of recurrent (\> 1) pulmonary embolism or deep vein thrombosis~2. Subjects, in the Investigator's opinion, unable to tolerate a right heart catheterization~3. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of Screening Visit~4. Subjects with Cardiac Resynchronization Device (CRT) implanted ≤ 3 months prior to enrollment~5. Subjects with a Glomerular Filtration Rate (GFR) \<25 ml/min who are non-responsive to diuretic therapy or who are on chronic renal dialysis~6. Subjects likely to undergo heart transplantation within 6 months of Screening Visit~7. Subjects with congenital heart disease or mechanical right heart valve(s)~8. Subjects with known coagulation disorders~9. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TREATMENT Group (Type: ACTIVE_COMPARATOR): Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
- CONTROL Group (Type: PLACEBO_COMPARATOR): Standard of care HF management

Based on this trial design, predict the completion outcome and termination type (if applicable).